Tuesday, June 4, 2019

Inhibrx Files For IPO

La Jolla-based biopharmaceuticals startup Inhibrx has just filed for an IPO, saying in an S-1 filing that it is looking to raise up to $74.75M in an IPO on the Nasdaq Global Market. Inhibrx has applied to trade as INBX. The IPO is being underwritten by Evercore ISI, Barclays, Nomura, and Raymond James. Inhibrx is backed by LAV Biosciences Fund and Viking

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.

---